Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Haws

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Pediatric Obesity|June 2, 2025
Clinical burden of hyperphagia, obesity and health outcomes in paediatric individuals with Bardet-Biedl syndrome: A CRIBBS data analysisJeremy Pomeroy, Uzoma Okorie, Jesse G Richardson, et al.
Clinical Genetics|February 3, 2022
Kidney failure in Bardet-Biedl syndromeJennifer R Meyer, Anthony D Krentz, Richard L Berg, et al.
Advances in Therapy|March 24, 2023
Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl SyndromeClaire Ervin, Lindsey Norcross, Usha G Mallya, et al.
Orphanet Journal of Rare Diseases|January 16, 2023
Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial resultsElizabeth Forsythe, Robert M Haws, Jesús Argente, et al.
The Lancet. Diabetes & Endocrinology|November 10, 2022
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label periodAndrea M Haqq, Wendy K Chung, Hélène Dollfus, et al.
Kidney International|August 5, 2020
An international cohort study of autosomal dominant tubulointerstitial kidney disease due to REN mutations identifies distinct clinical subtypesMartina Živná, Kendrah Kidd, Mohamad Zaidan, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Pediatric Obesity|June 2, 2025
Clinical burden of hyperphagia, obesity and health outcomes in paediatric individuals with Bardet-Biedl syndrome: A CRIBBS data analysisJeremy Pomeroy, Uzoma Okorie, Jesse G Richardson, et al.
Clinical Genetics|February 3, 2022
Kidney failure in Bardet-Biedl syndromeJennifer R Meyer, Anthony D Krentz, Richard L Berg, et al.
Advances in Therapy|March 24, 2023
Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl SyndromeClaire Ervin, Lindsey Norcross, Usha G Mallya, et al.
Orphanet Journal of Rare Diseases|January 16, 2023
Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial resultsElizabeth Forsythe, Robert M Haws, Jesús Argente, et al.
The Lancet. Diabetes & Endocrinology|November 10, 2022
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label periodAndrea M Haqq, Wendy K Chung, Hélène Dollfus, et al.
Kidney International|August 5, 2020
An international cohort study of autosomal dominant tubulointerstitial kidney disease due to REN mutations identifies distinct clinical subtypesMartina Živná, Kendrah Kidd, Mohamad Zaidan, et al.
Pageof 2